PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
Rhea-AI Summary
PacBio (NASDAQ: PACB) expanded its partnership with seqWell to distribute the LongPlex™ Multiplexing Kit, a scalable sample-prep solution optimized for PacBio HiFi sequencing. The kit uses tagmentation to fragment and index DNA, supporting multiplexing of up to hundreds of samples per run and workflows including low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing. The LongPlex kit is available now with global availability in 2026, and is positioned to reduce hands-on time and cost per sample for high-throughput projects.
Positive
- Adds scalable LongPlex distribution to PacBio product portfolio
- Supports multiplexing of up to hundreds of samples per run
- Targets low-pass WGS, plasmid, and microbial sequencing workflows
- Available now with global availability in 2026
Negative
- No financial or commercial terms disclosed in the announcement
- Full global availability not expected until 2026
News Market Reaction 13 Alerts
On the day this news was published, PACB declined 7.89%, reflecting a notable negative market reaction. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $40M from the company's valuation, bringing the market cap to $466M at that time.
Data tracked by StockTitan Argus on the day of publication.
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing
MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and multiplexing workflow solutions. Under the new agreement, PacBio will distribute seqWell’s LongPlex™ Multiplexing Kit, a scalable, easy-to-use sample preparation solution designed for use with PacBio HiFi sequencing and optimized for efficient transposase-based DNA fragmentation and multiplexing. LongPlex removes sample prep bottlenecks, enabling researchers to produce high-quality libraries quickly, support current studies cost-efficiently, and power the next wave of population-scale research.
This collaboration expands the portfolio of workflow options available to PacBio customers, complementing PacBio’s highly accurate long-long read technology with an additional flexible, high-throughput sample prep solution. The LongPlex™ Multiplexing Kit uses tagmentation to simultaneously fragment and index DNA for up to hundreds of samples in a single run, making it ideal for large-scale screening and targeted resequencing efforts.
“Expanding our partnership with seqWell is part of our commitment to meet researchers where they are with the flexibility, speed, and accuracy they need,” said David Miller, Vice President of Global Marketing at PacBio. “By offering LongPlex alongside our existing workflows, we’re giving customers more choice across high-throughput applications, especially where rapid, economical data generation is essential.”
Organizations such as Veil Genomics are already demonstrating the value of LongPlex for population-scale efforts.
“At Veil, our goal is to democratize genomic insights through scalable, cost-effective data,” said Josh Clevenger, Ph.D., Co-founder of Veil Genomics. “The LongPlex™ Multiplexing Kit has allowed us to continue to develop our low-pass WGS workflow, supporting efficient DNA fragmentation and multiplexing that let us process thousands of samples without compromising data quality for downstream analysis.”
By supporting sample prep across low-pass WGS, plasmid sequencing, and microbial sequencing, LongPlex extends options for researchers working in diverse fields. Its streamlined indexed tagmentation workflow reduces hands-on time while maintaining the performance required for high-quality sequencing data.
“We’re proud to expand our collaboration with PacBio, bringing LongPlex™ to more labs worldwide,” said Dan Calvo, President and CEO of seqWell. “This agreement reflects a shared vision to accelerate discovery by making innovative, practical sample prep tools widely available to genomic researchers.”
The LongPlex™ Multiplexing Kit is available today, with global availability in 2026, adding a scalable sample prep option to PacBio’s portfolio of sequencing solutions.
For more information about the LongPlex™ Multiplexing Kit and compatible workflows, please visit www.pacb.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About seqWell
seqWell creates scalable genomics technologies that simplify library preparation workflows and help scientists to unlock transformative discoveries with sequencing. seqWell offers a range of library prep products and tagmentation workflows designed to meet the throughput and cost demands of modern genomics applications including population-scale, short- and long-read sequencing initiatives. Learn more at www.seqwell.com or follow us on Linkedin.
About Veil Genomics
Veil Genomics is a precision genomics company dedicated to population-scale low-pass WGS and data-driven insights for health and agriculture. By combining innovative sequencing pipelines with powerful analytics, Veil delivers actionable genomic information to drive real-world impact.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, or quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, such as those in connection with seqWell’s LongPlex Multiplexing Kit, expanding sample prep and workflow options, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in new collaborations; the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8- K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts (PacBio)
Investors:
Media: pr@pacificbiosciences.com
FAQ
What did PacBio (PACB) announce on October 7, 2025 about seqWell?
How many samples can seqWell LongPlex multiplex for PacBio HiFi sequencing?
When will the LongPlex Multiplexing Kit be available globally for PACB customers?
Which sequencing workflows does LongPlex support with PacBio HiFi?
What operational benefits does LongPlex offer PacBio users?
Will the PacBio and seqWell agreement include pricing or revenue details for PACB investors?
